Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Abstract
A video abstract is now available for this publication, which can be viewed online. The video abstract can also be accessed on the article’s Figshare page here: https://doi.org/10.6084/m9.figshare.24749436 and in the parent article as Supplementary file 3. 2xeqpp-jg_FT7HrQkW1y9mVideo abstract: Integrated safety analysis of ritlecitinib in patients aged ≥ 12 years with alopecia areata (MP4 1.03 gb)Video abstract: Integrated safety analysis of ritlecitinib in patients aged ≥ 12 years with alopecia areata (MP4 1.03 gb) Video abstract: Integrated safety analysis of ritlecitinib in patients aged ≥ 12 years with alopecia areata (MP4 1.03 gb). In Supplementary file2, Table S11, “Lymphocytes, n/N1 (%)c, Grade 3 (200 to < 500/mm3)” row, “Any ritlecitinib (n=1294)” column, the data that previously read: “27/128 (2.1)” should have read: “27/1286 (2.1)” The original Supplementary file 2 has been corrected.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.